Evidence map›Paper›PMID 22077236›Full record

Trial reportThe New England journal of medicine2011

Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.

DCCT/EDIC Research Group, Ian H de Boer, Wanjie Sun, Patricia A Cleary, John M Lachin, Mark E Molitch, Michael W Steffes, Bernard Zinman

2 registry-linked trialsOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The New England journal of medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 255 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
255citing papers in PubMed, 7 pooled it
36.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00360815 nacompletednot on this map

Diabetes Control and Complications Trial (DCCT)

TypeinterventionalSponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Ran1983 to 1993Enrolled1,441ConditionsType 1 Diabetes MellitusArmsInsulin
NCT00360893 active not recruitingnot on this map

Epidemiology of Diabetes Interventions and Complications (EDIC)

TypeobservationalSponsorGeorge Washington UniversityRan1994 to 2027Enrolled1,441ConditionsType 1 Diabetes Mellitus
3 · Its place in the literature

Who cites it

255 citing papers in PubMed, 7 syntheses or guidelines pooled it, 574 citations in OpenAlex.

  1. Pooled it
  2. Glucose targets for preventing diabetic kidney disease and its progression.The Cochrane database of systematic reviews · 2017
    Pooled it
  3. Clinical significance of 'cardiometabolic memory': a systematic review of randomized controlled trials.Hypertension research : official journal of the Japanese Society of Hypertension · 2017
    Pooled it
  4. Pooled it
  5. Maintenance Dialysis throughout the World in Years 1990 and 2010.Journal of the American Society of Nephrology : JASN · 2015
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Renal outcomes in patients with type 1 diabetes and macroalbuminuria.Journal of the American Society of Nephrology : JASN · 2014
    Trial
  17. Trial
  18. Nurse practitioner care improves renal outcome in patients with CKD.Journal of the American Society of Nephrology : JASN · 2014
    Trial
  19. Trial
  20. Review

195 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

DCCT/EDIC Research Group
Ian H de Boer
Wanjie Sun
Patricia A Cleary
John M Lachin
Mark E Molitch
Michael W Steffes
Bernard Zinman
University of Washington · US

Funding

Randomized trial of vitamin D and omega-3 fatty acids for diabetic kidney diseaseR01DK088762 · NIDDK · UNIVERSITY OF WASHINGTON · PI DE BOER, IAN H · 2010 to 2019
$4.7M
Insulin Resistance in Chronic Kidney DiseaseR01DK087726 · NIDDK · UNIVERSITY OF WASHINGTON · PI DE BOER, IAN H · 2010 to 2013
$1.9M
Vitamin D metabolism and type 1 diabetes complicationsRC4DK090766 · NIDDK · UNIVERSITY OF WASHINGTON · PI DE BOER, IAN H · 2010 to 2010
$400k
NIDDK NIH HHS R01 DK087726NIDDK NIH HHS R01DK087726NIDDK NIH HHS R01 DK088762NIDDK NIH HHS R01DK088762NIDDK NIH HHS RC4 DK090766NIDDK NIH HHS RC4DK090766
6 · The paper itself

Abstract

backgroundAn impaired glomerular filtration rate (GFR) leads to end-stage renal disease and increases the risks of cardiovascular disease and death. Persons with type 1 diabetes are at high risk for kidney disease, but there are no interventions that have been proved to prevent impairment of the GFR in this population.

methodsIn the Diabetes Control and Complications Trial (DCCT), 1441 persons with type 1 diabetes were randomly assigned to 6.5 years of intensive diabetes therapy aimed at achieving near-normal glucose concentrations or to conventional diabetes therapy aimed at preventing hyperglycemic symptoms. Subsequently, 1375 participants were followed in the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study. Serum creatinine levels were measured annually throughout the course of the two studies. The GFR was estimated with the use of the Chronic Kidney Disease Epidemiology Collaboration formula. We analyzed data from the two studies to determine the long-term effects of intensive diabetes therapy on the risk of impairment of the GFR, which was defined as an incident estimated GFR of less than 60 ml per minute per 1.73 m(2) of body-surface area at two consecutive study visits.

resultsOver a median follow-up period of 22 years in the combined studies, impairment of the GFR developed in 24 participants assigned to intensive therapy and in 46 assigned to conventional therapy (risk reduction with intensive therapy, 50%; 95% confidence interval, 18 to 69; P=0.006). Among these participants, end-stage renal disease developed in 8 participants in the intensive-therapy group and in 16 in the conventional-therapy group. As compared with conventional therapy, intensive therapy was associated with a reduction in the mean estimated GFR of 1.7 ml per minute per 1.73 m(2) during the DCCT study but during the EDIC study was associated with a slower rate of reduction in the GFR and an increase in the mean estimated GFR of 2.5 ml per minute per 1.73 m(2) (P<0.001 for both comparisons). The beneficial effect of intensive therapy on the risk of an impaired GFR was fully attenuated after adjustment for glycated hemoglobin levels or albumin excretion rates.

conclusionsThe long-term risk of an impaired GFR was significantly lower among persons treated early in the course of type 1 diabetes with intensive diabetes therapy than among those treated with conventional diabetes therapy. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; DCCT/EDIC ClinicalTrials.gov numbers, NCT00360815 and NCT00360893.).

Indexed as

AdultCreatinineDiabetes Mellitus, Type 1Diabetic NephropathiesFemaleFollow-Up StudiesGlomerular Filtration RateGlycated HemoglobinHumansHypoglycemic AgentsInsulinInsulin Infusion SystemsKidney Failure, ChronicMaleMiddle AgedCreatinineGlycated HemoglobinHypoglycemic AgentsInsulin

Identifiers

PMID22077236
PMCPMC3270008
OpenAlexW2141495158

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.